Jiyeon Yang1, Pu Fang1, Daohai Yu1, Lixiao Zhang1, Daqing Zhang1, Xiaohua Jiang1, William Y Yang1, Teodoro Bottiglieri1, Satya P Kunapuli1, Jun Yu1, Eric T Choi1, Yong Ji2, Xiaofeng Yang1, Hong Wang2. 1. From the Centers for Metabolic Disease Research (J.Y.Y., P.F., L.Z., X.J., W.Y.Y., J.Y., X.Y., H.W.), Cardiovascular Research (J.Y.Y., D.Y., X.Y., H.W.), Department of Clinical Sciences, and Sol Sherry Thrombosis Research (J.Y.Y., S.P.K., X.Y., H.W.), Departments of Pharmacology, Physiology and Surgery (J.Y., E.T.C., H.W.), Temple University School of Medicine, Philadelphia, PA; Key Laboratory of Cardiovascular Disease and Molecular Intervention, Nanjing Medical University, China (Y.J.); Cardiovascular Research Institute and Key Laboratory of Cardiology, Shenyang Northern Hospital, Liaoning, P. R. China (D.Z.); and Institute of Metabolic Disease, Baylor Research Institute, Dallas, TX (T.B.). 2. From the Centers for Metabolic Disease Research (J.Y.Y., P.F., L.Z., X.J., W.Y.Y., J.Y., X.Y., H.W.), Cardiovascular Research (J.Y.Y., D.Y., X.Y., H.W.), Department of Clinical Sciences, and Sol Sherry Thrombosis Research (J.Y.Y., S.P.K., X.Y., H.W.), Departments of Pharmacology, Physiology and Surgery (J.Y., E.T.C., H.W.), Temple University School of Medicine, Philadelphia, PA; Key Laboratory of Cardiovascular Disease and Molecular Intervention, Nanjing Medical University, China (Y.J.); Cardiovascular Research Institute and Key Laboratory of Cardiology, Shenyang Northern Hospital, Liaoning, P. R. China (D.Z.); and Institute of Metabolic Disease, Baylor Research Institute, Dallas, TX (T.B.). yongji@njmu.edu.cn hongw@temple.edu.
Abstract
RATIONALE: Patients with chronic kidney disease (CKD) develop hyperhomocysteinemia and have a higher cardiovascular mortality than those without hyperhomocysteinemia by 10-fold. OBJECTIVE: We investigated monocyte differentiation in human CKD and cardiovascular disease (CVD). METHODS AND RESULTS: We identified CD40 as a CKD-related monocyte activation gene using CKD-monocyte -mRNA array analysis and classified CD40 monocyte (CD40+CD14+) as a stronger inflammatory subset than the intermediate monocyte (CD14++CD16+) subset. We recruited 27 patients with CVD/CKD and 14 healthy subjects and found that CD40/CD40 classical/CD40 intermediate monocyte (CD40+CD14+/CD40+CD14++CD16-/CD40+CD14++CD16+), plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine levels were higher in CVD and further elevated in CVD+CKD. CD40 and CD40 intermediate subsets were positively correlated with plasma/cellular homocysteine levels, S-adenosylhomocysteine and S-adenosylmethionine but negatively correlated with estimated glomerular filtration rate. Hyperhomocysteinemia was established as a likely mediator for CKD-induced CD40 intermediate monocyte, and reduced S-adenosylhomocysteine/S-adenosylmethionine was established for CKD-induced CD40/CD40 intermediate monocyte. Soluble CD40 ligand, tumor necrosis factor (TNF)-α/interleukin (IL)-6/interferon (IFN)-γ levels were elevated in CVD/CKD. CKD serum/homocysteine/CD40L/increased TNF-α/IL-6/IFN-γ-induced CD40/CD40 intermediate monocyte in peripheral blood monocyte. Homocysteine and CKD serum-induced CD40 monocyte were prevented by neutralizing antibodies against CD40L/TNF-α/IL-6. DNA hypomethylation was found on nuclear factor-κB consensus element in CD40 promoter in white blood cells from patients with CKD with lower S-adenosylmethionine / S-adenosylhomocysteine ratios. Finally, homocysteine inhibited DNA methyltransferase-1 activity and promoted CD40 intermediate monocyte differentiation, which was reversed by folic acid in peripheral blood monocyte. CONCLUSIONS: CD40 monocyte is a novel inflammatory monocyte subset that appears to be a biomarker for CKD severity. Hyperhomocysteinemia mediates CD40 monocyte differentiation via soluble CD40 ligand induction and CD40 DNA hypomethylation in CKD.
RATIONALE: Patients with chronic kidney disease (CKD) develop hyperhomocysteinemia and have a higher cardiovascular mortality than those without hyperhomocysteinemia by 10-fold. OBJECTIVE: We investigated monocyte differentiation in human CKD and cardiovascular disease (CVD). METHODS AND RESULTS: We identified CD40 as a CKD-related monocyte activation gene using CKD-monocyte -mRNA array analysis and classified CD40 monocyte (CD40+CD14+) as a stronger inflammatory subset than the intermediate monocyte (CD14++CD16+) subset. We recruited 27 patients with CVD/CKD and 14 healthy subjects and found that CD40/CD40 classical/CD40 intermediate monocyte (CD40+CD14+/CD40+CD14++CD16-/CD40+CD14++CD16+), plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine levels were higher in CVD and further elevated in CVD+CKD. CD40 and CD40 intermediate subsets were positively correlated with plasma/cellular homocysteine levels, S-adenosylhomocysteine and S-adenosylmethionine but negatively correlated with estimated glomerular filtration rate. Hyperhomocysteinemia was established as a likely mediator for CKD-induced CD40 intermediate monocyte, and reduced S-adenosylhomocysteine/S-adenosylmethionine was established for CKD-induced CD40/CD40 intermediate monocyte. Soluble CD40 ligand, tumor necrosis factor (TNF)-α/interleukin (IL)-6/interferon (IFN)-γ levels were elevated in CVD/CKD. CKD serum/homocysteine/CD40L/increased TNF-α/IL-6/IFN-γ-induced CD40/CD40 intermediate monocyte in peripheral blood monocyte. Homocysteine and CKD serum-induced CD40 monocyte were prevented by neutralizing antibodies against CD40L/TNF-α/IL-6. DNA hypomethylation was found on nuclear factor-κB consensus element in CD40 promoter in white blood cells from patients with CKD with lower S-adenosylmethionine / S-adenosylhomocysteine ratios. Finally, homocysteine inhibited DNA methyltransferase-1 activity and promoted CD40 intermediate monocyte differentiation, which was reversed by folic acid in peripheral blood monocyte. CONCLUSIONS:CD40 monocyte is a novel inflammatory monocyte subset that appears to be a biomarker for CKD severity. Hyperhomocysteinemia mediates CD40 monocyte differentiation via soluble CD40 ligand induction and CD40 DNA hypomethylation in CKD.
Authors: Khurram Nasir; Eliseo Guallar; Ana Navas-Acien; Michael H Criqui; João A C Lima Journal: Arterioscler Thromb Vasc Biol Date: 2005-06-23 Impact factor: 8.311
Authors: Adam M Zawada; Kyrill S Rogacev; Stephan H Schirmer; Martina Sester; Michael Böhm; Danilo Fliser; Gunnar H Heine Journal: Immunobiology Date: 2012-07-25 Impact factor: 3.144
Authors: Kyrill S Rogacev; Sarah Seiler; Adam M Zawada; Birgit Reichart; Esther Herath; Daniel Roth; Christof Ulrich; Danilo Fliser; Gunnar H Heine Journal: Eur Heart J Date: 2010-10-12 Impact factor: 29.983
Authors: Daqing Zhang; Xiaohua Jiang; Pu Fang; Yan Yan; Jian Song; Sapna Gupta; Andrew I Schafer; William Durante; Warren D Kruger; Xiaofeng Yang; Hong Wang Journal: Circulation Date: 2009-10-26 Impact factor: 29.690
Authors: Anouk A J Hamers; Huy Q Dinh; Graham D Thomas; Paola Marcovecchio; Amy Blatchley; Catherine S Nakao; Cheryl Kim; Chantel McSkimming; Angela M Taylor; Anh T Nguyen; Coleen A McNamara; Catherine C Hedrick Journal: Arterioscler Thromb Vasc Biol Date: 2019-01 Impact factor: 8.311
Authors: Haitao Shen; Na Wu; Gayani Nanayakkara; Hangfei Fu; Qian Yang; William Y Yang; Angus Li; Yu Sun; Charles Drummer Iv; Candice Johnson; Ying Shao; Luqiao Wang; Keman Xu; Wenhui Hu; Marion Chan; Vincent Tam; Eric T Choi; Hong Wang; Xiaofeng Yang Journal: Front Biosci (Landmark Ed) Date: 2019-01-01
Authors: Dong Ni; TingTing Tang; Yifan Lu; Keman Xu; Ying Shao; Fatma Saaoud; Jason Saredy; Lu Liu; Charles Drummer; Yu Sun; Wenhui Hu; Jahaira Lopez-Pastrana; Jin J Luo; Xiaohua Jiang; Eric T Choi; Hong Wang; Xiaofeng Yang Journal: Front Immunol Date: 2021-05-18 Impact factor: 7.561